Gamida Cell (GMDA) Downgraded to Hold at ValuEngine

ValuEngine lowered shares of Gamida Cell (NASDAQ:GMDA) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, ValuEngine reports.

A number of other equities analysts have also recently issued reports on GMDA. Zacks Investment Research upgraded Gamida Cell from a hold rating to a buy rating and set a $15.00 price objective for the company in a report on Friday, March 1st. Oppenheimer set a $20.00 price objective on Gamida Cell and gave the company a buy rating in a report on Tuesday, February 26th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $18.67.

Shares of NASDAQ:GMDA traded up $0.20 during trading hours on Wednesday, hitting $7.95. 4,607 shares of the company’s stock traded hands, compared to its average volume of 17,205. Gamida Cell has a 1 year low of $6.65 and a 1 year high of $15.41. The firm has a market capitalization of $192.57 million and a PE ratio of -0.75.

Gamida Cell (NASDAQ:GMDA) last announced its earnings results on Friday, February 8th. The company reported ($14.23) earnings per share (EPS) for the quarter. Analysts expect that Gamida Cell will post -1.51 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in Gamida Cell in the 4th quarter valued at about $88,000. Millennium Management LLC purchased a new stake in Gamida Cell in the 4th quarter valued at about $210,000. Delek Group Ltd. purchased a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $298,000. Finally, FMR LLC purchased a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $1,243,000. 1.76% of the stock is owned by institutional investors.

About Gamida Cell

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Further Reading: Trading based on a resistance level

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.